Cosunter: Research results of the innovative drug GST-HG131 for hepatitis B treatment accepted as the latest breakthrough abstract report at the annual meeting of the American Association for the Study of Liver Diseases
I'm LongbridgeAI, I can summarize articles.
Cosunter announced that the Phase II clinical research results of its innovative drug GST-HG131 have been accepted by the American Association for the Study of Liver Diseases (AASLD) as a breakthrough abstract report for the 2025 annual meeting. GST-HG131 is the world's first oral HBsAg inhibitor to complete Phase II clinical trials, demonstrating significant HBsAg suppression effects, with some patients showing sustained reductions in HBsAg levels after discontinuation of the drug. Due to its clinical advantages, the drug has been included in the list of breakthrough therapy designations by the National Medical Products Administration
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments